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developing nonhealing neurotrophic ulcers. In addi-
tion to the neuropathy, hyperglycaemia will inhibit
white cell function, thus predisposing the patient to
infection (see also D 1.4, Diabetic Foot p 5148). A
comprehensive approach to treating patients with dia-
betes would include proper footwear, with attention
to areas of trauma from poorly fitting shoes (see D
4.2.2, Foot Care, p 5165). Patients with nonheaIing
ulcers often need to be treated in the hospital to pro-
vide comprehensive management, including wound
care and eventually systemic antibiotics. In addition,
aggressive control of blood sugar is warranted in these
patients, with an attempt to maintain fasting blood
sugars below 120 mg/dL and postprandial sugars less
than 180 mg/dL. Chronic management should
attempt to normalise glycohaernoglobin levels to less
than 7.0% (see Recommendation 23, p 569).
Hypcrlipidnclllin
The lipid risk profile for patients with peripheral arte-
rial disease is similar between those with claudication
and those with CLI. There arc no data regarding rec-
ommendations in the severe leg ischaemia patient
population. However, extrapolation from patients
with intermittent claudication as well as from the
National Cholesterol Education Program Guidelines
would recommend aggressive treatment of LDL cho-
lesterol levels and attempts to raise the HDL choles-
terol and lower triglyceride levels . Therefore, patients
with CLI should have an LDL cholesterol level main-
tained at 100 mg/dL or less (sec Recommendation 25,
p 570). The goals of therapy are to reduce the systemic
risk of myocardial infarction and cardiovascular
death, as well as to delay the progression of peripher-
al atherosclerosis.
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o 4.3
Pharmacotherapy for Critical limb Ischaemia
04.3.1
Introduction
For decades, pharmaceutical and clinical research aimed
at improving the morbidity of claudication has centred
around vasodilators. Direct-acting vasodilators can
increase blood flow in normal resting skeletal muscle.
However, it is unlikely that any vasodilator can signifi-
cantly increase blood flow distal to a physical occlusion.
Autoregulatory mechanisms in skeletal muscle beds
produce dilation in response to ischaemia; hence,
vasodilators will increase blood flow primarily to non-
ischaemic areas. The concept of vasodilatation has
moved to vasoreactive or vasorecruiting drugs and
more recently to agents improving unbalanced or com-
promised microcirculation distal to an arterial obstruc-
tion. Another approach is to search for compounds that
improve the blood rheology. The use of "thrombolytic
drugs in CLI is also to be considered, most often to be
followed by endovascular or surgical treatment.
The ideal treatment for critical limb ischaemia must be
the elimination or bypass of the occlusions in the larger
arteries, but this is often impossible or else it fails. An
alternative in these cases is to try to modify the conse-
quences of the low perfusion pressure on the distal
microcirculation sufficiently by' some form of pharma-
cotherapy to reverse the rest pain and avoid amputation.
Pharmacological management of CLI must be based
on an improved understanding of its pathophysiology.
The main components, lack of autoregulation of the
microvascular flow-regulating system and inappropri-
ate activation of the microvascular defence system, are
both thought to be significantly regulated by prostacy-
clin.' Breakdown of the microvascular flow-regulating
system is manifested in particular by abnormal vaso-
motion and a maldistribution of blood flow away from
the nutritive skin capillaries. Activation of the microvas-
cular defence system results in interacting activation of
white blood cells, platelets, and the damaged endotheli-
um . The resultant capillary obstruction, increased capil-
lary permeability, tissue oedema, and the liberation of
activated products of leukocytes, such as oxygen free
radicals, platelet-activating factor, and proteolytic




Prostanoids have been shown to have beneficial
effects on most of the microcirculatory components by
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Table 41: Trials comparing long-term (7-28 days'treatment) infusion of prostanoid with placebo or reference drug in patients
with severe arterial disease (Fontaine III and IV) a
n Trial
Author (% diabetic) Drug Dosage Follow-up End points Results p design
Sakaguchi 65 PGE1 (IA) 0.05 or 0.15 end of ulcer size reduced by 0.039 DB
198415 niacinate oral ng/kg/min x 24 infusion pain higher dose
(200 mg continuous infusion vs. niacinate
6 x daily) for 2-6 wk + lower dose
Bohme et al, 34 PGE1 (IA) 10-20 pg/60 end of ulcer size reduced NS 0
198716 vsATP minx23days infusion rest pain reduced NS
Trubestein et al, 57 PGE1vs30 20 mg over 60 3wk analg. cons. reduced < 0.04 0
198717 mgATP(IA) min daily x 3 wk ulcer size reduced < 0.02
amputation reduced 0.02
Diehmetal, 46 PGE1vs 60 pg/4 h/ 1 mo pain reduced <0.04 DB
19885 placebo (IV) day x3wk analg. cons. reduced < 0.02
clinical stage improved 0.007
Ciprostene Study 211 PGE1vs 120 ng/kg/min 4 mo ulcer size reduced < 0.005 DB
Group 199}lS placebo (IV) x 8 h/day x 7 days by 50%
ICAI Study 1,560 PGE1(IV) vs 60 pg /day 6 mo CLI reduced odds 0.002 0
Group, 1998 19 routine x 28 days disappearance ratio 0.73
treatment
Triibestein et al, 70 PGE1(IV) 2 x 40 J.Ig over 6mo rest pain reduced NS 0
1989:0 vs pentoxifylline 2 h daily x 4 wk analg. cons. reduced < 0.005
ulcer size reduced < 0.05
Balzer et al, 113 lIoprost vs 0.5-2 ng/kg/min end of analg. cons. reduced <0.05 DB
198711 (34%) placebo (IV) x 6 h x 14 days infusion
Diehm et al, 101 Iloprost vs up to 2 ng/kg/ end of ulcer size reduced < 0.05 DB
1989:2 placebo (IV) min x 6 h x 28 days infusion
Norgren et al, 103 lIoprost vs 0.5-2 ng/kg/min 6mo ulcer size reduced NS DB
1990:3 (32%) placebo (IV) x 6 h x 14 days
Brocket al, 109 Iloprost vs 0.5-2 ng/kg/min end of ulcer size reduced < 0.05 DB
1990:' (100%) placebo (IV) x 6 h x 28 days infusion rest pain reduced < 0.05
UK Study Group, 151 Iloprost vs up to 2 ng/kg/min 1 mo ulcer healing reduced <0.05 DB
199125 (31%) placebo (IV) x 6 h daily x 28 days 6 mo ulcer healing reduced < 0.01
Guilmot et al, 128 Iloprost vs up to 2 ng/kg/min 1 mo rest pain Reduced <0.05 DB
199126 (58%) placebo (IV) x 6 hr daily x 21 days 1 mo rest pain Reduced NS
NS=not statistically significant; PGIz=prostaglandin 12; PGE1=prostaglandin E1; analg cons=analgesic consumption; Cl.Iecritical
limb ischaemia; O=open; DB=double-blind
preventing the reciprocal potentiation of platelet acti-
vation, leukocyte activation, and the damaged vascu-
lar endothelium. 1 This is probably the reason why
prostanoids have, in the last few years, been the most
widely tested group of drugs in this condition.
Initially, PCEl was mainly evaluated by intraarterial
administration because of its well-known rapid pul-
monary inactivation.? Intravenous studies with PCEl
were subsequently undertaken when it was shown
that after a temporary inactivation of PCEl by the
lung, 13,14-dihydro-PCEl is formed. At least in regard
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to antiplatelet activity, this has been shown to display
biological activity comparable with the parent com-
pound PCEl) Furthermore, intraarterial and intra-
venously infused PCEl in patients with intermittent
claudication caused a similar systemic inhibition of
zymosan-stimulated radical production.' The clinical
benefit of the intravenous administration route was
later shown in a limited number of patients with PAD
stage III in a single Cerman centre by Diehm et al.s
Since the first report of the effects of intraarterial
infusion of prostaglandin El in four patients with
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unreconstructable leg ischaernia,« there have been
seven short-term (3-4 days) trials using PGEI and
PGh intraarteriallyzw or intravenously10,l1,12,13 show-
ing inconclusive evidence of their efficacy in patients
with unreconstructable limb ischaemia. Table 41 sum-
marises 13 subsequently performed long-term ran-
domised open or double-blind trials comparing
intraarterial or intravenous infusions of PGEI,
ciprostene, or iloprost, both more stable prostacyclin
analogs, with placebo in patients with advanced
chronic limb ischaemia (Fontaine stages III and
IV).5,14,15,16,17,18,19,20,21,22,23,24,25,26
These studies all followed a similar protocol,
although the duration of treatment varied from 2 to 4
weeks. The clinical end points used were relief of rest
pain, analgesic consumption, or promotion of ulcer
healing. All of these long-term studies administering
prostanoids for more than 7 days showed a benefit in
at least one of the chosen end points, with only two tri-
als failing to reach statistical significance. The
response seemed to be greater when prostanoids were
administered for 4 weeks, compared with administra-
tion for 2 or 3 weeks. Data on major amputation at 3 or
6 months' follow-up were available in three of the ilo-
prost studiesp,25,26 Patients who received iloprost
were significantly less likely to have undergone a
major amputation than patients in the placebo groups
(23% vs 39%, P < 0.05) during the treatment and fol-
low-up period. Most importantly, patients who
received iloprost had a significantly greater probabili-
ty of completing the follow-up period alive with both
legs than patients who received placebo (35% vs 55%,
P < 0.05),27
Although these results are impressive, it is also
important to be aware of their limitations. Total ulcer
healing was not used because it was too uncommon an
event after a few weeks of treatment. Measurement of
the decrease in greatest diameter of the ulcer is subject
to observer variation. Furthermore, where photo-
graphs were used in attempt to overcome observer
variation, they were often of inconsistent quality. With
respect to pain relief, it has to be kept in mind that this
outcome measure is based on a subjective assessment
by the individual patient. A further bias may have been
introduced by the side effects of prostanoids, allowing
the observer to have an idea of the patient's treatment
group. Further clinical trials with prostanoids are
required to show evidence of efficacy as primary med-
ical treatment of critical limb ischaemia.
The prostanoid investigated in the largest number
of patients with advanced chronic limb ischaemia in
controlled randomised studies is iloprost. The avail-
able data support its use in patients with CLI unsuit-
able for any reopening procedure or in whom revas-
cularisation attempts have failed. There is no available
technique for identifying those who will respond, but
its relative safety suggests that it should be tried in all
such patients unless an early amputation is clearly
unavoidable. Its use as an adjuvant to high-risk revas-
cularisation procedures is being assessed.
Recommendation 85: Use of prostanoids in critical
limb ischaemia
Patients who have a viable limb in whom revascu-
larisation procedures are impossible, carry a poor
chance of success or have previously failed, and
particularly when the alternative is amputation,
may be treated with prostanoids.
Critical Issue 29: Use of prostanoids in earlier
stages of critical limb ischaemia
There is a need to test prostanoids in patients with
earlier stages of critical limb ischaemia and in
whom intervention is predicted to have a relatively
low success rate as most randomised, open or dou-
ble-blind trials with intraarterial or intravenous
prostanoids have been performed in patients with
end-stage critical limb ischaemia.
D4.3.3
Pharmacotherapy other Than Prostanoids
Antiplatelet drugs
Long-term treatment with aspirin and ticlopidine is
shown to reduce the progression of femoral athero-
sclerosis.> Whether these antiplatelet agents can pre-
vent thrombosis in prosthetic femoropopliteal grafts is
uncertain (see also D 4.13.2, Antiplatelet Therapy, p
5209). It should be noted that in a recent study the
favourable effect of ticlopidine over 24 months has
been demonstrated in patients after saphenous vein
bypass grafting.>
There is a strong case for treatment of all patients
with PAD with long-term antiplatelet therapy such
as aspirin, ticlopidine, or clopidogrel (see
Recommendation 29, p 573). Meta-analysis of the Final
Report of the Second Cycle of the Antiplatelet Trialistsi
Collaboration shows clear evidence that these
antiplatelet agents produce a 25% reduction of other
vascular events (stroke, myocardial infarction, and vas-
cular death) and also improve patency of peripheral
arteries and grafts.v However, neither these trials nor
the recent CAPRIE study were conducted in PAD
patients with rest pain and ischaemic ulcers,»
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Anticoagulants
No clinical trials have been published on the use of
unfractionated heparin for critical limb ischaemia,
although recently an open study using low-molecular-
weight heparin did show encouraging results with a
decrease of rest pain and healing of ulcers previously
resistant to treatrnent.v None of the publications on
the effect of anticoagulation exclusively concerns such
patients. The use of oral anticoagulants improved the
long-term patency of infrainguinal bypass grafts, but
this single study should be confirmed.P (see also D
4.13, Adjuvant Therapy After Revascularisation, p
5209).
Haeinodiluiion
The benefit of haemodilution has not been properly
evaluated in patients with chronic CLI; however, if a
patient's haematocrit remains 50% despite cessation of
smoking and rehydration, haemodilution may be con-
sidered.
Critical Issue 30: Use of long-term oral antithrom-
botic therapy in terms of limb survival
There is a need to determine whether long-term
oral antithrombotic therapy is useful in terms of
limb survival.
Defibrinogenating agents
Despite many open trials reporting promIsmg
results with the use of defibrinogenating agents in
50% to 80% of treated patients34•35,36 two recent place-
bo-controlled double-blind studies with ancrod
failed to show any benefit in terms of healing of
ischaemic ulcers or in reducing subsequent amputa-
tion rateY.3S
Other vasoactive drugs
Although a few vasoactive drugs may have a benefi-
cial effect in vasospastic diseases by increasing cuta-
neous capillary flow, there is little substantive evi-
dence to support their use on patients with critical
limb ischaemia.39.~Ml.42.43.H Most vasoactive drugs me
said to have vasodilatory properties, whereas some
claim to alter blood rheology, improve tissue oxidative
potential in the ischaemic state, or act by increasing
collateral flow through a serotonergic blocking effect.
Some of these drugs have been shown to be efficacious
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in intermittent claudication (see B 4.2,
Pharmacotherapy for Symptoms of Intermittent
Claudication, p 576), but none have been shown to
have a clinically beneficial effect in large properly con-
trolled studies in patients with severe chronic limb
ischaemia.
L-Arginine is the precursor of endogenous nitric
oxide that is a potent vasodilator, acting via the intra-
cellular second-messenger cyclic guanosine
monophosphate (cGMP). In healthy humans, L-argi-
nine induces' peripheral vasodilation and inhibits
platelet aggregation because of increased nitric oxide
production.w- The clinical benefit of this in the treat-
ment of CLI remains to be established.
Parenteral pentoxifyIline have been investigated in
patients with critical limb ischaemia in two double-
blind placebo-controlled multicentre trials. In the two
trials, 600 mg pentoxifyIline was administered intra-
venously twice daily for up to 21 days. In the
European Study Group, the severity of rest pain was
consistently and significantly lower in the pentoxi-
fylline group, but unfortunately the use of analgesics
was allowed and uncontrolled (intention-to-treat
analysis)." Treatment response was not influenced by
the presence of diabetes or by eligibility for surgery.
The subsequent double-blind Norwegian study fol-
lowed the same protocol but in a smaller number of
patients. This study confirmed a trend in the amelio-
ration of rest pain but did not reach statistical signifi-
cance between the two treatment groups."
Recommendation 86: Vasoactive drugs in treatment
of critical limb ischaemia
Very few vasoactive drugs have been properly
investigated in patients with critical limb
ischaemia. Because the results are unconvincing or
negative, current drugs cannot be recommended in
patients with chronic critical limb ischaemia.
04.3.4
Gene-Induced Therapeutic Angiogenesis
Recent investigations have established the feasibility
of using recombinant formulations of angiogenic
growth factors to expedite or augment collateral
artery development in animal models of hind limb
ischaemia. This novel strategy for the treatment of
vascular insufficiency has been termed "therapeutic
angiogcnesis.?" No recombinant protein formulation
of an angiogenic cytokine has yet been made available
for human studies of CLI. Gene transfer constitutes an
alternative strategy for accomplishing therapeutic
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angiogenesis. In the case of vascular endothelial
growth factor (VEGF), this is a particularly appealing
strategy because the VEGF gene encodes a signal
sequence that permits the protein to be naturally
secreted from intact cells'v; the impact of the gene
product is thus not limited to the transfected cells, but
can be amplified considerably by paracrine effects of
the gene product (VEGF protein) on endothelial cells
responsible for neovascularisation.
Gene therapy for therapeutic angiogenesis was per-
formed initially in patients with CLI by arterial gene
transfer of VEGF plasmid DNA (phVEGF165) .51 Using
a dose-escalating design, treatment was initiated with
100 pg phVEGF165• Three patients presenting with rest
pain (but no gangrene) and treated with 1,000 pg were
subsequently shown at 1 year follow-up to have
improved blood flow to the ischaernic limb and
remain free of rest pain.v With the increase in dose of
phVEGF165 to 2,000 pg, angiographic and histological
evidence of new blood vessel formation became
apparent.v
More recently, the use of intramuscular (1M) gene
transfer, employed initially as a means of treating
patients in whom vascular disease in the ischemic
limb was too extensive to permit an intraarterial
approach, resulted in marked improvement in collat-
eral vessel development in patients with CLI.5-t The 1M
strategy was performed in 10 limbs of nine patients
with nonhealing ischaemic ulcers (n = 7/10) or rest
pain (n = 10/10) attributable to peripheral arterial dis-
ease. A dose of 4,000 pg phVEGF165 was injected direct-
ly into the muscles of the ischaemic limb. Gene expres-
sion was documented by a transient increase in VEGF
serum levels using an enzyme-linked immunosorbent
assay (ELISA). The ankle:brachial pressure index
improved significantly (from 0.33 ± 0.05 to 0.48 ( 0.03,
P = 0.02); newly visible collateral blood vessels were
documented by contrast angiography in seven limbs;
and MRA showed qualitative evidence of improved
distal flow in eight limbs. Ischaemic ulcers healed or
markedly improved in four of seven limbs, including
successful limb salvage in three patients recommended
for below-knee amputation. Complications were limit-
ed to transient lower extremity oedema in six patients,
consistent with VEGF enhancement of vascular perme-
ability. These findings may be cautiously interpreted to
indicate that intramuscular injection of naked plasmid
DNA achieves constitutive overexpression of VEGF
sufficient to induce therapeutic angiogenesis in select-
ed patients with CU. Certain patients in this initial
cohort and several others subsequently (seven limbs in
six patients) satisfied diagnostic criteria for Buerger's
disease.v
Critical Issue 31: Use of gene-induced angiogenesis
in patients with critical limb ischaemia
There is a need, suggested by preliminary studies,
for properly controlled studies of the use of gene-
induced angiogenesis in treatment of patients with
critical limb ischaemia.
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04.4
Introduction to Interventional Treatment for
Critical Limb Ischaemia
The decision to proceed with vascular intervention on
a patient with CLI is relatively straightforward,
because most require revascularisation to avoid major
amputation. The decision regarding the most appro-
priate intervention, however, is complex, with a num-
ber of factors requiring consideration. In addition to
the mortality and morbidity, comorbid risk factors and
life expectancy must be weighed against the initial
success and long-term durability of the chosen inter-
vention. The literature can provide only broad direc-
tion in the decision-making process because most
series report best results in a selected patient popula-
tion characterised by more favourable anatomic lesions.
Ideally, the patient should be treated with the least
risky and least morbid but most successful an-d
durable procedure. Comorbid risk factors will modify
this ideal to give priority to patient safety. High-risk,
frail patients may be best treated with less invasive
interventions, even though durability may not be opti-
mal. In some patients, revascularisation procedures
should be abandoned for primary amputation when
patient factors suggest extremely high morbidity and
mortality or the arterial anatomy predicts a poor out-
come of intervention. Conversely, the temptation to
pursue the least invasive procedure even in the
healthy individual should be resisted. In such cases,
the durability of the procedure over many years is
important in reducing lifetime morbidity and cost.
In the following discussions, the results of open sur-
gical and endovascular procedures are presented sep-
arately in relation to proximal and distal levels of
occlusive disease: aortoiliac or infra inguinal. This is
followed by a discussion of the usually preferred
option for each broad category of lesion: aortoiliac or
infrainguinal. The disease at each level not only must
be considered in terms of its own severity, but all lev-
els of disease must be combined in considering the
best approach to limb salvage and improved function.
This is particularly true of CLI, in which multilevel
occlusive disease predominates and poor runoff is
almost the norm. Although it is necessary to present
the results of open surgical and endovascular inter-
ventions separately, they ultimately must be consid-
ered together. Unfortunately, there is a tendency to
choose either surgical or percutaneous revascularisa-
tion techniques exclusively in a given patient, but a
multidisciplinary approach results in better choices, as
may combining procedures. Excellent results may be
obtained when endovascular and open surgical proce-
dures are combined (eg, combined iliac dilatation with
distal surgical revascularisation).
Given the multilevel nature of the disease in
patients with CLI and the lack of sufficient data in the
literature dealing with each of the multiple combina-
tions of disease, it is not possible to make recommen-
dations that cover all eventuality. In principle, how-
ever, the most appropriate treatment should be
applied to each individual occlusive lesion, and com-
binations of treatment modalities should be consid-
ered as well as procedures that span more than one
level of disease. These and the other considerations
previously mentioned should be kept in mind in the
discussions that follow. In the following sections,
results from a variety of studies are presented. It is
imperative that the individual caring for the patient
with CLI review the results obtained at their own
institution (see also Recommendation 77, p 5150, and
D 4.15, Vascular Registry Data, p 5220).
Recommendation 87: Choosing between techniques
with comparable short- and long-tenn benefit
When two techniques of revascularisation
(endovascular and open surgery) give equivalent
short-term and long-term benefit, the technique
with the least morbidity and mortality must be
used first. Cost also should be considered.
Recommendation repeatedfrom preoioussection, sec
v5150
Recommendation 77:
It is recommended that all units dealing toith critical
limb iscltacntia mail/tail/ accurate, audited records
for patients treated and their progress. The minimum
follOW-III' anabjsis should be ill terms of l-ycar re-
interventions, re-admissions, amputation rates,
mortality, and, ideally, other outcome measures.
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